InvestorsHub Logo
Followers 2
Posts 429
Boards Moderated 0
Alias Born 07/13/2016

Re: None

Tuesday, 09/05/2017 4:12:43 PM

Tuesday, September 05, 2017 4:12:43 PM

Post# of 38634
I like the idea that the company said something. They indicated they are "strongly confident" in the commercialization of Rexista. Could that be an indication that they are hopeful to get a tentative approval for Rexista with a abuse deterrent label for IV on 9/25? Or does it mean they expect to get shot down this time and then go back for a second shot at it later? I can't say but we should know before the end of the month.

If they get a tentative approval and then win the court battle, then we really have something and the stock will jump. Of course, Purdue can tell if they are not going to win and would likely settle first.

I like the fact they are strengthening the patents surrounding PODRAS as I think this is where the really big money is.

They did not say anything wonderful about Seroquel and Focalin sales. I think they would have if there was something to talk about on that front.

There was nothing said about cash or the balance sheet. That is all important and an unfortunate omission. They have rising legal costs, rising testing costs and, as best we know, not a lot of cash. Either our new CFO delivers cash from some sale of product rights or some partnership agreement or there would seem to be a high likelihood of some type of new equity being sold.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPCI News